A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer
Status: Active, no longer recruiting
Phase of Trial: Phase II/III
Latest Information Update: 14 Mar 2019
Price : $35 *
At a glance
- Drugs Metformin (Primary) ; Carboplatin; Paclitaxel
- Indications Adenocarcinoma; Endometrial cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 07 Mar 2018 Status changed from recruiting to active, no longer recruiting.
- 23 Feb 2017 Status changed from suspended to recruiting.